Background-Cardiac magnetic resonance (CMR) is considered the reference standard for assessment of left ventricular ejection fraction (LVEF) and myocardial damage. However, few studies have evaluated the relationship between CMR findings and patient outcome, and of these, most are small and none multicenter. We performed an international, multicenter study to assess the prognostic importance of routine CMR in patients with known or suspected heart disease. Methods and Results-From 10 centers in 6 countries, consecutive patients undergoing routine CMR assessment of LVEF and myocardial damage by cine and delayed-enhancement imaging (DE-CMR), respectively, were screened for enrollment. Clinical data, CMR protocol information, and findings were collected at all sites and submitted to the data coordinating center for verification of completeness and analysis. The primary end point was all-cause mortality. A total of 1560 patients (age, 59Ϯ14 years; 70% men) were enrolled. Mean LVEF was 45Ϯ18%, and 1049 (67%) patients had hyperenhanced tissue (HE) on DE-CMR indicative of damage. During a median follow-up time of 2.4 years (interquartile range, 1.2, 2.9 years), 176 (11.3%) patients died. Patients who died were more likely to be older (PϽ0.0001), have coronary disease (Pϭ0.004), have lower LVEF (PϽ0.0001), and have more segments with HE (PϽ0.0001). In multivariable analysis, age, LVEF, and number of segments with HE were independent predictors of mortality. Among patients with near-normal LVEF (Ն50%), those with above-median HE (Ͼ4 segments) had reduced survival compared to patients with below-or at-median HE (Pϭ0.02). Conclusions-Both LVEF and amount of myocardial damage as assessed by routine CMR are independent predictors of all-cause mortality. Even in patients with near-normal LVEF, significant damage identifies a cohort with a high risk for early mortality. (Circ Cardiovasc Imaging. 2011;4:610-619.)
This technique offers high-spatial resolution imaging of pathophysiological processes related to myocardial infarction (MI) [22] [23] [24] [25] or nonischemic heart disease 12,26 -29 that was previously achievable only by postmortem histopathological evaluation. Given its advantages, DE-CMR increasingly is being used as a surrogate end point in clinical trials that test new therapies for acute MI. 30 However, similar to cine-CMR, of the few studies that have assessed the prognostic importance of DE-CMR, most were small, and none were multicenter. The purpose of the present study was to examine the prognostic value of a routine CMR assessment of LVEF and myocardial damage in a broad, real-life population enrolled consecutively from several centers.
Methods

Study Design
This observational, multicenter study was funded in part by Siemens Medical Solutions (Erlangen, Germany), which did not have access to the data. Data collection and analysis were independently performed at Duke University Medical Center, which served as the data coordinating center (DCC). The lead investigators had full access to the data and wrote the article without need for approval by the sponsor. The participating centers were located in the United States (3), Europe (England, 1; Germany, 3; France, 1; The Netherlands, 1), and South America (Brazil, 1). Among the 10 sites, 7 were university hospitals, and 3 were tertiary cardiovascular care centers. Institutional Review Board approval was received at each center according to local regulations. In most centers (nϭ8), data were collected retrospectively, and deidentified data were submitted to the DCC. Therefore, informed consent was waived by the Institutional Review Board. In 2 centers, patients were enrolled prospectively (nϭ646), and written informed consent was obtained from all patients.
Patients and Data Collection
An outline of patient screening, enrollment, and data collection is shown in Figure 1 . At each cardiovascular MRI center, consecutive patients of either gender undergoing an MRI (either cardiac, vascular, or both) were screened. All patients who completed a routine cardiac study for assessment of both function and myocardial damage (with a complete stack of cine and DE imaging) and with at least 1 year of follow-up (unless death occurred within the follow-up period) were enrolled.
The participating centers decided a priori on the study design and a limited number of data items to be collected by each site. A standard data collection form, including demographic information, a targeted medical history, CMR protocol information and findings, and follow-up information, was completed for each patient. The medical history was obtained by review of medical records by the local study investigators and was limited to determining the presence or absence of the following: known or suspected heart disease, known or suspected CAD, and MI Յ7 days before the index CMR scan. Follow-up status was ascertained by review of medical records, interrogation of the Social Security Death Index for US sites, and physician and patient/family telephone contact. The prespecified primary end point was all-cause mortality. Hard copies of the data collection forms were stored at each study site. All data except for the patient identifiers were submitted electronically to the DCC, where their completeness was verified. All submitted patients with complete data were included in the final analysis.
Cardiac Magnetic Resonance
Imaging Protocol
Images were acquired on clinical 1.5-T Siemens scanners using phased-array receiver coils according to the routine scan protocol at each site. A typical protocol was as follows: First, localizers were acquired to identify the cardiac position and the standard long-and short-axis of the heart, and then cine images were acquired in multiple short-axis (to cover the LV from base to apex) and 3 long-axis views (2, 3, and 4 chamber) using a steady-state freeprecession (SSFP) sequence. 31 For DE-CMR, an inversion-recovery Figure 1 . Outline of patient enrollment and data collection. The first 3 steps occurred at the individual participating centers and involved patient screening, data collection from enrolled patients, and data submission after deidentification. Steps 4 and 5 included data verification and analysis at the DCC. At each cardiovascular MRI center, consecutive patients of either gender undergoing an MRI (either cardiac, vascular, or both) were screened. All patients screened were subsequently enrolled unless they had only a vascular study (no cardiac imaging), had an incomplete cardiac study (eg, cine imaging without DE-CMR), did not have a full year of follow-up, or did not give informed consent (at sites enrolling patients prospectively). After submission of enrolled patient data to the DCC, 22 patients were excluded because of withdrawal of consent (nϭ1), incomplete CMR protocol information or CMR findings (nϭ19), or incomplete follow-up data (nϭ2). CMR indicates cardiac magnetic resonance; DCC, data coordinating center; DE, delayed enhancement.
pulse-sequence for T1 weighting was required, 32 with either an SSFP or gradient-recalled echo (GRE) data readout, and images were obtained 10 to 20 minutes after gadolinium contrast injection (0.1-0.2 mmol/kg) in the identical views as cine-CMR.
Image Analysis
The study site investigators analyzed images on locally available workstations and were blinded to follow-up data. The LVEF was determined on cine images either by planimetry of endocardial and epicardial contours in both diastole and systole or by a visual assessment providing a numeric estimate of LVEF following each site's institutional protocol (ie, following the same process used for their routine clinical interpretations). For the assessment of regional wall motion, the standard American Heart Association 17-segment model was used 33 with a 5-point scoring system (0ϭnormal; 1ϭmild, moderate hypokinesis; 2ϭsevere hypokinesis; 3ϭakinesis; 4ϭdyskinesis). To provide an estimate of the extent of regional wall motion abnormalities, a mean wall motion score was computed by summation of all scores divided by the number of segments. Similarly, the presence and location of hyperenhanced tissue (HE) on DE-CMR, which was assumed to represent irreversibly damaged myocardial tissue, 12, 25 was assessed by visual inspection using the standard 17-segment model. 33 At the DCC, regional enhancement was classified according to the presence or absence of HE within each segment. Study investigators had been instructed to score HE on a 5-point scale (0ϭno hyperenhancement; 1ϭ1%-25%; 2ϭ26%-50%; 3ϭ51%-75%; 4ϭ76%-100%) 22 ; however, after data collection, it became clear that the 5-point scale was used to index the spatial area of HE by some centers and the maximum transmurality of HE at any given point by other centers. Thus, for the purpose of data analysis performed at the DCC, the total LV amount of HE was expressed simply as the number of segments with any HE (ie, for each patient, HE score could range from 0 -17).
Statistical Analysis
Continuous data are presented as meanϮSD or in cases where the distribution was not normal, as median and interquartile range. Two-sample t tests were used to compare mean values of continuous data between 2 groups. Chi-square tests were used to compare discrete data between groups. Based on the observed median value of number of segments with HE, the study population was divided into 2 groups, and the survival of both cohorts was further analyzed according to the Kaplan-Meier method. The significance of differences in event rates between groups was assessed with the Cox regression analysis. Multivariable Cox regression analysis was performed using stepwise regression techniques, including all clinical variables (that were not collinear) and the best CMR covariates (see Table 1 for covariates) to identify the best overall model. Because the unadjusted relationship between the number of segments with HE and outcomes was nonlinear, a transformation (segments with HE 2 ) was implemented. The incremental prognostic value of CMR variables was examined by the change in likelihood ratio 2 of the model after addition of each candidate variable. To account for possible differences according to study site, it was included as a covariate in all multivariable analyses. Results were expressed as hazard ratios with associated 95% CIs. The relationships between mortality and the categories of LVEF and segments with HE were assessed using Cox regression analysis adjusted for site and age. Based on these models, predicted event rates were calculated at a fixed time point of 2 years. All statistical tests were 2 tailed, and PϽ0.05 was regarded as significant.
Results
Study Population
Patients undergoing an MRI study between September 1999 and January 2004 were screened for study enrollment at 10 centers ( Figure 1 ). All patients screened were subsequently enrolled unless they only had a vascular study (no cardiac imaging), had an incomplete cardiac study (eg, cine imaging without DE-CMR), did not have a full year of follow-up, or did not give informed consent (at sites enrolling patients prospectively). Data on 1582 patients who met inclusion criteria were submitted to the DCC (the last data collection form was submitted in June 2006). After data submission, 22 patients were excluded because of incomplete CMR data (nϭ19), unknown follow-up date (nϭ2), or withdrawal of patient consent (nϭ1). Each site contributed on average 156Ϯ109 patients (range, 50 -346); 925 patients were from US sites, 561 were from Europe, and 74 were from Brazil. The most frequently used pulse sequence for DE-CMR was the 2D segmented inversion-recovery GRE sequence, which was used in 1431 (92%) studies. Rarely, other pulse sequences were used, including the 2D real-time, subsecond SSFP sequence 34 in 93 (6%) studies followed by the 3D segmented GRE sequence in 22 (1.4%), 2D segmented SSFP sequence in 7 (0.4%), and the 2D subsecond GRE sequence in 6 (0.4%).
The general characteristics of the final study population comprising 1560 patients are shown in Table 1 . Overall, the mean age of the group was 59.0Ϯ14.1 years. The majority (64%) had known or suspected CAD, and a few patients (nϭ77) had an MI within 7 days before the CMR study. The mean LVEF was relatively preserved (45Ϯ18%). The majority (71%) had at least 1 regional wall motion abnormality. HE was found in 1049 (67%) patients, and for the entire population, patients had a median of 4.0 segments with HE (interquartile range, 0, 9.0). Compared to patients without HE, patients with HE were older, more often men, and more likely to have known or suspected heart disease and CAD. They also were more likely to have a lower LVEF and a higher wall motion score. Table 1 also shows the baseline characteristics in the subgroups with and without CAD. Patients with CAD were older, had lower LVEF, and had more segments with HE than those without CAD.
Survival Analysis
The median follow-up time was 2.4 years (interquartile range, 1.2, 2.9 years), and the longest follow-up was 5.8 years. A total of 176 (11.3%) patients died during the follow-up period. The hazard ratios for all-cause mortality are shown in Table 2 . Patients who died were more likely to be older (PϽ0.0001), have CAD (Pϭ0.004), have lower LVEF (PϽ0.0001) and higher wall motion score (PϽ0.0001), and have more segments with HE (PϽ0.0001). In multivariable Cox regression analysis in which all candidate variables from univariable analysis were considered, age, LVEF, and the number of segments with HE were significant independent predictors of all-cause mortality. We assessed the incremental predictive value of LVEF and HE by creating 3 different models: (1) clinical parameters alone, (2) clinicalϩLVEF, and (3) clinicalϩLVEFϩnumber of HE segments (Table 3 ). The addition of LVEF to clinical parameters led to a significant improvement in the predictive value of the model as reflected by the increase in global 2 (83.02 versus 126.01, PϽ0.0001). The addition of segments with HE resulted in further significant improvement in the model for predicting all-cause mortality as the 2 increased to 137.87 (PϽ0.001). Figure 2 illustrates Kaplan-Meier survival curves (adjusted for age and study site) stratified according to the amount of HE.
Patients with above-median (Ͼ4 segments) HE had significantly reduced survival compared to patients with below-or at-median (Յ4 segments) HE (PϽ0.002) (Figure 2A ). When only patients with near-normal LVEF (Ն50%) were considered, again, patients with above-median HE had reduced survival compared to patients with less HE (Pϭ0.02) ( Figure 2B ).
Given that LVEF was determined by planimetry (nϭ1022; mean, 44.1Ϯ18.7%) or estimated visually (nϭ538; mean, 47.9Ϯ17.2%) following each site's institutional protocol, these subgroups were further evaluated separately. Cox regression analysis showed that the hazard ratio for mortality by planimetered LVEF (0.965) was nearly identical to that by visual estimation (0.964) and to the population as a whole (0.964). Multivariable analysis demonstrated that in the subgroup with LVEF determined by planimetry, the same variables were associated with mortality as in the entire population (Table 2) . Figure 3A details the relationship between categories of LVEF and all-cause mortality. To account for possible differences in follow-up time among categories, mortality rates were calculated for a fixed time point of 2 years for this analysis. For each decrement in LVEF, there was a steadily increasing event rate (PϽ0.0001). Likewise, Figure 3B demonstrates that increasing number of segments with HE was associated with higher mortality rates (PϽ0.0001). However, the relationship was slightly different from LVEF in that mortality rates appeared to be similar in groups with Յ4 segments with HE.
In the cohort of patients with known or suspected CAD (nϭ1006), again, age, LVEF, and number of segments with HE were significant independent predictors of all-cause mortality (Table 4 ). In patients without CAD, age and LVEF were independent predictors of mortality. Although the number of segments with HE did not reach statistical significance, the cohort without CAD comprised a smaller population (nϭ554), and the hazard ratios for all 3 variables (LVEF, age, and number of segments with HE) were nearly identical to the cohort with CAD, suggesting a similar risk for death related to these parameters in both groups.
Discussion
Recent advances in CMR technology allow a robust, highly accurate, and reproducible assessment of cardiac function and myocardial damage within the same examination. Thus, CMR has become an important noninvasive test for assessment of cardiac patients in clinical routine. 35 Published studies indicate that CMR for detection of MI is accurate 36 and provides results equal or superior to radionuclide imaging. 23, 37 Additionally, CMR is increasingly used for the evaluation of nonischemic cardiomyopathies and offers unique diagnostic information on the underlying etiology. 38 However, despite the diagnostic utility, few studies have assessed the prognostic importance of findings on a routine CMR examination. To our knowledge, the current study is the largest as well as the first multicenter investigation to evaluate the prognostic significance of LVEF and myocardial damage as determined by CMR. Abbreviations as in Table 1 . *All models were adjusted for study site.
Several studies have established that LVEF is a strong predictor of adverse outcome in various patient cohorts. 5, 6, 8 Previous investigations ascertaining the prognostic importance of LVEF used established imaging modalities, such as echocardiography, 5,7,9,39 radionuclide ventriculography, 6, 10 and ECG-gated single-photon emission CT, 11 and generally included large numbers of patients. Among the largest studies investigating the prognostic value of LVEF determined by ECG-gated single-photon emission CT was that by Travin et al 11 of 3207 patients. Using echocardiography, Gottdiener et al 39 investigated the relationship of LVEF and mortality in 5532 patients, whereas Zaret et al 10 included 3197 patients in whom LVEF was measured with radionuclide ventriculography. Curtis et al 6 investigated the relationship between LVEF measurements by echocardiography and radionuclide or contrast ventriculography and mortality in 7788 patients. Although CMR allows the determination of LVEF with superior precision and reproducibility, agreement of LVEF measurements among different modalities used in the same patient is moderate at best. 19 Therefore, the relationship between CMRdetermined LVEF and mortality requires separate evaluation.
To date, the largest published CMR studies evaluating prognosis were single-center investigations involving 513 patients 40 and 857 patients. 16 The present multicenter study in 1560 patients corroborates those previous reports in that CMR-determined LVEF was found to be an important predictor of adverse outcome.
Additionally, the current results suggest that the association between LVEF and mortality holds across the full spectrum of LVEF. This is in contrast to some studies where higher LVEF values were associated with a linear decrease in mortality up to an LVEF of 45%, but further increases in LVEF above this point were not associated with further reductions in mortality. 6 The possible difference in findings may be due to dissimilarities in the patient population. In the current study, a broad spectrum of patients with known or suspected heart disease presenting for routine CMR imaging were included, and there was a nearly 5-fold difference in mortality between patients in the lowest and highest LVEF groups. In the investigation by Curtis et al, 6 enrollment was restricted to stable outpatients given a clinical diagnosis of heart failure, and there was only a 2.2-fold relative difference Figure 2 . Kaplan-Meier estimates of survival. Survival curves in all patients (A) and in patients with LVEF Ն50% (B) stratified according to the amount of HE (adjusted for age and study site). In both the entire group and the patients with near-normal LVEF, those with above-median HE (Ͼ4 segments) had reduced survival compared with patients with below-or at-median HE (Յ4 segments). HE indicates hyperenhanced tissue; LVEF, left ventricular ejection fraction. Figure 3 . Mortality rate as a function of LVEF and amount of myocardial damage. The height of the bar and the number within represent the observed mortality rate at 2 years and total number of subjects for each category of LVEF (A) and HE (B). Solid lines represent Cox regression estimates (smoothed) of 2-year mortality adjusted for age and study site. Dashed lines represent 95% CIs. With each decrement in LVEF, there was a steadily increasing mortality rate. Likewise, increasing number of segments with HE was associated with higher mortality rates, although rates appeared to be similar in groups with Յ4 segments of HE. Abbreviations as in Figure 2. in mortality rates. Moreover, in the study by Curtis et al, neither the technique (echocardiography, equilibrium radionuclide angiography, or contrast ventriculography was used) nor interpretation of LVEF measurement was standardized.
In addition to the accurate assessment of LVEF, CMR provides high-resolution images of irreversible myocardial damage. 12, 27, 41 Of the studies that have assessed the prognostic importance of CMR-identified myocardial damage, 12, 13, 15, [42] [43] [44] none were multicenter, and in most, the primary end point was a composite, including "softer" events such as hospitalizations, occurrence of arrhythmias, and MI. 12, 18, 42 Only a few studies used all-cause mortality as a primary end point. Yan et al 15 demonstrated in 144 patients with prior MI that certain infarct characteristics (ie, extent of periinfarct zone) on DE-CMR predicted all-cause mortality independent of age and LVEF. Kim et al 17 studied patients with suspected CAD and without a history of clinical MI. The presence of unrecognized non-Q-wave MI on DE-CMR was associated with an 11-fold higher mortality rate. In the largest study to date assessing the prognostic significance of DE-CMR, Cheong et al 16 evaluated 857 patients from a tertiarycare center and demonstrated that a myocardial scar index independently predicted all-cause mortality or cardiac transplantation. The results of the present multicenter study are consistent with these prior investigations. Moreover, similar to the study by Cheong et al, we found that even in patients with near-normal LVEF (Ն50%) the presence of substantial myocardial damage identifies a cohort with increased risk for all-cause mortality. Thus, CMR may be a useful risk stratification tool in patients generally considered to be at low risk based on LVEF criteria.
Several possible mechanisms have been proposed in linking myocardial damage and increased mortality. Experimental studies have shown that abnormal conduction properties within or surrounding myocardial scar are critical for reentry circuits to form, which are believed to be an important electrophysiological substrate for ventricular tachyarrhythmias [45] [46] [47] and sudden cardiac death. 48 Initial studies have shown that DE-CMR may be helpful in identifying patients at risk for ventricular tachycardia among those with prior infarcts 43, 44 as well as nonischemic cardiomyopathy. 12, 13 These investigations suggest a potential role of DE-CMR in risk stratification for cardiac arrhythmias and sudden death as well as for selection of patients for implantable cardioverter-defibrillator therapy.
Limitations
Enrollment was prospective in 2 centers and retrospective in 8. Clinical variables such as the presence of CAD were obtained by review of medical records by local site investigators but did not require specific test results to be submitted to the DCC. The findings on routine CMR were not compared to a comprehensive list of traditional clinical risk factors known to be associated with adverse outcome because data collection was limited to a few prespecified variables. Likewise, we do not have quantitative measures of cardiac morphology, such as LV end-diastolic and end-systolic volumes. However, we demonstrated in a relatively large study population that myocardial hyperenhancement (indicating damage) has prognostic importance independent of LVEF, which is believed to be one of the strongest and most robust predictors of mortality. We did not ascertain the cause of death, and the primary end point was chosen to be all-cause rather than cardiac mortality. However, many believe that the most appropriate end point is total mortality (recommended by a policy statement written by the North American Society for Pacing and Electrophysiology 49 ) because it is objective, clinically relevant, and unbiased, which often is not the case for cardiac mortality. 50 We did not collect data regarding the clinical indications for CMR, which limits our ability to generalize the findings to other cohorts. However, patients were consecutively enrolled from 10 busy CMR centers across Europe, the United States, and Brazil; the inclusion criteria ( Figure 1 ) were broad; and the sample size was relatively large. Hence, we believe that the patient cohort is likely to be reflective of the current real-life clinical practice of CMR. On this issue, it is informative that a recent multicenter study (using many of the same CMR centers as the present study) reported the most common indications for CMR were evaluation of cardiomyopathy/myocarditis (32%), risk stratification in suspected coronary disease (31%), and assessment of viability (15%). 35 In one third of patients, LVEF was assessed visually. However, because the same process used for routine clinical interpretations was followed at each site, this again reflects the real-life clinical practice of CMR. Moreover, the results ( Figure 3A) clearly demonstrate a steadily increasing event rate with each decrement in LVEF, suggesting that the main conclusions would not be substantially changed if all studies had been assessed quantitatively. The presence and extent of HE was interpreted qualitatively by different readers at each site. Although all sites used a standard 17-segment and 5-point scoring model, 36 we found that some centers scored hyperenhancement based on the maximum transmural extent at any given point in the segment rather than the area of hyperenhancement within the segment. This precluded calculating the amount of HE as a percentage of LV mass as described previously, 17 and the absolute inflection point at which an increase in mortality risk occurs could not be accurately determined in this study. However, the principal relationship between HE and mortality could be established. We did not differentiate CAD-type hyperenhancement from other non-CAD-type patterns. Although both have been shown to be associated with adverse events, there may be differences in the prognostic importance between damaged tissue from MI or nonischemic heart diseases. Similarly, although our results demonstrate that lower LVEF (compared with higher LVEF) and more HE (compared with less HE) portend worse prognosis, one should not assume that LVEF or hyperenhancement has a uniform effect on mortality across the cardiac disorders included in the current broad population. Finally, there could be a potential bias in the estimated mortality rates because patients were not censored during year 1 except for those who died.
Conclusions
In patients undergoing a routine CMR study, including cine and delayed-enhancement imaging, both LVEF and the amount of myocardial tissue damage are independent predictors of all-cause mortality. Furthermore, even in patients with near-normal LVEF who generally are considered to be at low risk, significant myocardial damage identified a cohort with significantly worse prognosis. These findings warrant future studies to investigate the role of CMR in clinical management decisions based on risk stratification. 
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